Physician profile
Ann Doan-DO Bass
NPI 1104925171
$1,727,538.47
in general payments reported to CMS, 2019-2025
83 companies · $265K in 2025
The $265K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $382K · 2020: $178K · 2021: $143K · 2022: $276K · 2023: $284K · 2024: $199K · 2025: $265K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $436K · Consulting Fee: $153K · Travel and Lodging: $88K · Honoraria: $47K · Food and Beverage: $24K · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $436,255.50 |
| Consulting Fee | $153,020.97 |
| Travel and Lodging | $88,287.54 |
| Honoraria | $46,965.00 |
| Food and Beverage | $24,131.76 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $304,955.86 | 2019-2025 | |
| Emd Serono, INC. | $292,649.68 | 2019-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $237,485.85 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Alexion Pharmaceuticals, INC. | $151,207.58 | 2019-2025 | Soliris, Ultomiris |
| Tg Therapeutics, INC. | $125,515.44 | 2021-2025 | Briumvi |
| Novartis Pharmaceuticals Corporation | $106,161.15 | 2019-2025 | Kesimpta |
| E.R. Squibb & Sons, L.L.C. | $90,895.23 | 2020-2025 | Zeposia |
| Horizon Therapeutics Plc | $88,534.19 | 2021-2023 | Uplizna |
| Biogen, INC. | $85,755.73 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Celgene Corporation | $42,827.67 | 2019-2025 | Zeposia |
| Sanofi-Aventis U.S. LLC | $42,143.54 | 2019-2022 | |
| Lilly USA, LLC | $37,757.05 | 2019-2025 | Zepbound, Kisunla, Amyvid |
| Amgen INC. | $29,657.72 | 2019-2025 | Uplizna |
| Ares Trading Sa | $22,531.29 | 2023-2024 | Mavenclad |
| Merck Kgaa | $17,900.00 | 2021-2024 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharma Ag | $13,868.80 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $13,116.23 | 2020-2025 | Acthar |
| Banner Life Sciences, LLC | $4,560.00 | 2022 | |
| Hoffmann-La Roche Limited | $4,000.00 | 2022 | |
| F. Hoffmann-La Roche Ag | $3,149.04 | 2019-2021 | |
| Abbvie INC. | $1,483.67 | 2019-2025 | Duopa, Qulipta, Ubrelvy |
| Genentech, INC. | $1,369.83 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $748.64 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $744.61 | 2019-2025 | Nuplazid |
| Ucb, INC. | $590.07 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biohaven Pharmaceuticals, INC. | $501.42 | 2021 | |
| Abbott Laboratories | $488.53 | 2019-2023 | Infinity |
| Pfizer INC. | $462.36 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $443.73 | 2019-2024 | Ingrezza, Ongentys |
| Argenx US, INC. | $350.10 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Livanova USA, INC. | $338.88 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $331.02 | 2019-2020 | |
| Medtronic, INC. | $318.17 | 2022-2024 | Percept Pc Brainsense, Sensight, Intellis Adaptivestim |
| Lundbeck LLC | $292.68 | 2019-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $287.49 | 2019-2021 | |
| Grifols USA, LLC | $268.45 | 2019-2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $267.76 | 2019-2025 | Crexont, Rytary |
| Vanda Pharmaceuticals INC. | $240.14 | 2025 | Ponvory |
| Ge Healthcare | $235.04 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $200.31 | 2022 | |
| Eisai INC. | $191.64 | 2020-2024 | |
| Merz Pharmaceuticals, LLC | $165.49 | 2022-2025 | Inbrija, Ampyra, Xeomin |
| Ani Pharmaceuticals, INC. | $155.22 | 2022-2025 | Purified Cortrophin Gel |
| Csl Behring | $155.00 | 2019-2024 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $139.40 | 2023-2025 | Hyqvia, Gammagard |
| Novo Nordisk INC | $135.58 | 2025 | Wegovy, Rybelsus, Ozempic |
| Jazz Pharmaceuticals INC. | $133.69 | 2019-2024 | |
| Mdd US Operations, LLC | $132.37 | 2020-2023 | Gocovri |
| Kyowa Kirin, INC. | $130.64 | 2019-2021 | |
| Axsome Therapeutics, INC. | $114.33 | 2023-2025 | Symbravo, Sunosi |
| Sk Life Science, INC. | $111.63 | 2021-2023 | |
| Adamas Pharmaceuticals, INC. | $104.93 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $98.37 | 2020-2021 | |
| Insightec,INC | $84.54 | 2024 | Exablate |
| Octapharma USA, INC. | $79.81 | 2022-2025 | Panzyga |
| Janssen Biotech, INC. | $73.36 | 2025 | |
| Acorda Therapeutics, INC | $65.41 | 2020-2023 | Inbrija, Ampyra |
| Assertio Therapeutics, INC. | $61.47 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $60.91 | 2025 | Tascenso Odt, Bafiertam |
| Janssen Pharmaceuticals, INC | $60.14 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $59.16 | 2019-2021 | |
| Allergan, INC. | $55.70 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $47.92 | 2023-2024 | Aptiom |
| Kedrion Biopharma, INC. | $47.76 | 2024 | Gammaked, Koate, Albuked |
| Janssen Scientific Affairs, LLC | $40.39 | 2024-2025 | |
| Radius Health, INC. | $37.57 | 2020-2023 | Tymlos |
| Alnylam Pharmaceuticals INC. | $37.40 | 2024 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $36.63 | 2024-2025 | Nuedexta, Rexulti |
| Inspire Medical Systems, INC. | $31.75 | 2025 | Inspire |
| Averitas Pharma INC. | $30.40 | 2023 | Qutenza |
| Mallinckrodt Enterprises LLC | $28.83 | 2019 | |
| Saluda Medical Americas, INC. | $27.45 | 2023 | Evoke Scs |
| Boston Scientific Corporation | $25.51 | 2024 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $23.49 | 2025 | |
| Vertical Pharmaceuticals, LLC | $19.44 | 2019 | |
| Grt US Holding, INC. | $19.36 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.21 | 2024 | Horizant |
| Tanabe Pharma America, INC. | $18.76 | 2022 | |
| Bausch Health US, LLC | $18.61 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $12.27 | 2020 | |
| Merz North America, INC. | $11.98 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,990.88 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.